| Name | Title | Contact Details |
|---|
PharmaBlock Sciences (Nanjing), Inc. is a leading innovative chemistry products and services provider throughout the pharmaceutical R&D process. Its core businesses include: a catalog of specially designed scaffolds and building blocks; custom synthesis; process development; manufacturing of key intermediates and RSMs; and FTE services. The company was listed on Shenzhen Exchange Stock in China on November 10, 2017. PharmaBlock has rapidly gained recognition for its outstanding capability in the design, synthesis, and supply of lab scale building blocks. Building on that success, the company acquired Shandong Diai Biotechnology Co., Ltd. as its pilot plant and manufacturing site in 2016, and is providing scale-up synthesis and manufacturing of key intermediates/RSMs. PharmaBlock is now committed to a more comprehensive and long-term service to valued customers.
Validic provides a simple connection to secure, standardized data from the newest, most popular and most specialized digital health technologies - from wellness applications and wearables to fitness equipment and clinical devices. Mobile health technologies are reshaping patient engagement and population management opportunities for healthcare companies. Validic is powering this ecosystem to allow for the accelerated deployment of healthcare companies` strategic initiatives. Validic`s clients include health systems and providers, health plans and payers, corporate wellness companies, pharmaceuticals, health IT vendors, as well as app and device manufacturers.
Dice Financial Svc Group is a Mitchell, SD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
ForSight VISION5, Inc. (www.forsightvision5.com), was founded in January of 2011 as the fifth company to emerge from the ophthalmic incubator ForSight Labs, LLC (www.forsightlabs.com). ForSight VISION5 is focused on developing non-invasive drug delivery products that replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy. ForSight VISION5`s lead product candidate is the Helios insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to receive medication continually. The Helios insert is restricted to investigational use only and has not been approved by the Food and Drug Administration or any other regulatory authority for commercial distribution.
Med-X Global is an LLC formed in the State of New Jersey. We operate as international revenue cycle consultants, third-party medical claims administrators and payment collectors adjudicating emergency medical claims for highly accredited foreign hospitals. Med-X also serves the ancillary emergency provider community in the foreign marketplace to include air and ground ambulance entities as well as premier urgent care centers and physician administered emergency sites. The majority of Med-X`s hospital clients operate clinically sophisticated facilities accredited by the General Heath Council (CSG) while still others are accredited by the Joint Commission International (JCI) reflecting a standard of care that typically meets or even exceeds the U.S. benchmark for quality providers.